Kybora
Biopharma Deals 2024

Key Biopharma Deals of 2024

January 16, 2025
News
Trends, Insights, and Strategic Implications The biopharma industry in 2024 experienced a transformative year marked by high-value mergers and acquisitions (M&A), strategic licensing agreements, significant investments in radiopharmaceuticals, and an…
READ MORE
Biopharma Deals 2024

Key Biopharma Deals of 2024

January 16, 2025
News
Trends, Insights, and Strategic Implications The biopharma industry in 2024 experienced a transformative year marked by high-value mergers and acquisitions…
READ MORE
Welcome

KYBORA Welcomes Stefan Bluemmers as Managing Director

January 13, 2025
News
Princeton, NJ – January 13, 2025 – KYBORA, a global healthcare advisory firm and investment bank, is proud to announce that Stefan…
READ MORE
Accelerated Approval PRV

Accelerated Approval (AA) and PRV Grant: Implications of the FDA’s Updated Guidance

January 9, 2025
News
Executive Summary – The U.S. Food and Drug Administration (FDA)’s December 2024 guidance,“Expedited Program for Serious Conditions – Accelerated Approval…
READ MORE
KYBORA's Charitable Work

Empowering Dreams through Foundation Rwanda’s KYBORA Program

January 7, 2025
News
Ange's Entrepreneurial Spirit Shines Bright Ange's journey is one of perseverance and hope. After gaining extensive experience in the liquor…
READ MORE
Navigating the Complexities of PRVs in the Context of AA Withdrawals

Navigating the Complexities of Priority Review Vouchers in the Context of Accelerated Approval Withdrawals

December 19, 2024
News
Executive Summary – The FDA’s Accelerated Approval (AA) pathway has been instrumental inexpediting treatments for serious conditions, but recent scrutiny,…
READ MORE
Recent Facts & Figures related to Priority Review Vouchers Value - 2020 to 2024

Recent Facts & Figures related to Priority Review Vouchers Value – 2020 to 2024

December 18, 2024
News
Executive Summary – As the year draws to a close, we present an updated analysis of the Priority Review Vouchers…
READ MORE
European Pharma Group Proposes TEE Voucher System to Revitalize Antibiotics R&D

European Pharma Group Proposes TEE Voucher System to Revitalize Antibiotics R&D

December 10, 2024
News
Executive Summary – The European pharmaceutical industry is advocating for the implementation of a Transferable Exclusivity Extension (TEE) system to…
READ MORE
KYBORA Advises Xbrane on Global Licensing Agreement with Intas

KYBORA Advises Xbrane on Global Licensing Agreement with Intas

December 5, 2024
News
KYBORA, a leading global advisory firm specializing in biopharma transactions, served as the exclusiveadvisor to Xbrane Biopharma AB (Nasdaq Stockholm:…
READ MORE
Navigating Priority Review Voucher Eligibility: Beyond Rare Pediatric Disease Designation

Navigating Priority Review Voucher Eligibility: Beyond Rare Pediatric Disease Designation

December 4, 2024
News
Executive Summary – A pediatric drug can qualify for a Priority Review Voucher (PRV) upon FDAapproval, even without receiving a…
READ MORE
Banner

Understanding the Role of the Not Same Active Moiety Principle in RPDD and PRV Evaluations

December 2, 2024
News
Executive Summary – The FDA’s “not same active moiety” principle plays a key role in evaluating eligibility for Rare Pediatric…
READ MORE
The latest trends on biotech companies with negative enterprise values

The Latest Trends on Biotech Companies with Negative Enterprise Values: Insights and Implications

August 13, 2024
News
In the post Covid era, the spotlight turned sharply towards biotech companies with negative enterprise value (EV). While many saw…
READ MORE
KYBORA Advises Lupin

KYBORA Advises Lupin on the Divestiture of U.S. Commercial Women’s Health Specialty Business to Evofem

August 1, 2024
News
Global pharma major Lupin announced that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, a U.S.…
READ MORE

TYPE & ENTER: